DPYD Antibody (monoclonal) (M01)
Mouse monoclonal antibody raised against a partial recombinant DPYD.
|Application ||WB, IF, E|
|Calculated MW||111401 Da|
|Other Names||Dihydropyrimidine dehydrogenase [NADP(+)], DHPDHase, DPD, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase, DPYD|
|Target/Specificity||DPYD (NP_000101, 1 a.a. ~ 110 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.|
|Format||Clear, colorless solution in phosphate buffered saline, pH 7.2 .|
|Storage||Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.|
|Precautions||DPYD Antibody (monoclonal) (M01) is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a pyrimidine catabolic enzyme and the initial and rate-limiting factor in the pathway of uracil and thymidine catabolism. Mutations in this gene result in dihydropyrimidine dehydrogenase deficiency, an error in pyrimidine metabolism associated with thymine-uraciluria and an increased risk of toxicity in cancer patients receiving 5-fluorouracil chemotherapy. Two transcript variants encoding different isoforms have been found for this gene.
Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients. Kristensen MH, et al. J Int Med Res, 2010 May-Jun. PMID 20819423.Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. Kim SR, et al. Chemotherapy, 2010. PMID 20714149.Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study. Fari?a-Sarasqueta A, et al. Cancer Chemother Pharmacol, 2010 Jul 28. PMID 20665215.Absence of large intragenic rearrangements in the DPYD gene in a large cohort of colorectal cancer patients treated with 5-FU-based chemotherapy. Par? L, et al. Br J Clin Pharmacol, 2010 Aug. PMID 20653680.[Correlation between clinicopathological factors and enzymatic activity of orotate phosphoribosyl transferase (OPRT), dihydropyrimidine dehydrogenase (DPD) in esophageal cancer] Takemura M, et al. Gan To Kagaku Ryoho, 2010 Jul. PMID 20647710.
If you have any additional inquiries please email technical services at email@example.com.